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Abstract
Introduction Familial hypercholesterolaemia (FH), an
autosomal dominant disorder of lipid metabolism, results in
accelerated onset of atherosclerosis if left untreated. Lifelong
treatment with diet, lifestyle modifications and statins enable
a normal lifespan for most patients. Early diagnosis is critical.
This protocol trials a primary care-based model of care (MoC)
to improve detection and management of FH.
Methods and analysis Pragmatic cluster intervention
study with pre-post intervention comparisons in Australian
general practices. At study baseline, current FH detection
practice is assessed. Medical records over 2 years are
electronically scanned using a data extraction tool (TARB-Ex)
to identify patients at increased risk. High-risk patients are
clinically reviewed to provide definitive, phenotypic diagnosis
using Dutch Lipid Clinic Network Criteria. Once an index
family member with FH is identified, the primary care team
undertake cascade testing of first-degree relatives to identify
other patients with FH. Management guidance based on
disease complexity is provided to the primary care team.
Study follow-up to 12 months with TARB-Ex rerun to identify
total number of new FH cases diagnosed over study period
(via TARB-Ex, cascade testing and new cases presenting).
At study conclusion, patient and clinical staff perceptions
of enablers/barriers and suggested improvements to the
approach will be examined. Resources at each stage
will be traced to determine the economic implications of
implementing the MoC and costed from health system
perspective. Primary outcomes: increase in number of index
cases clinically identified; reduction in low-density lipoprotein
cholesterol of treated cases. Secondary outcomes: increase
in the number of family cases detected/contacted; cost
implications of the MoC.
Ethics and dissemination Study approval by The University
of Notre Dame Australia Human Research Ethics Committee
Protocol ID: 0 16 067F. Registration: Australian New Zealand
Clinical Trials Registry ID: 12616000630415. Information
will be disseminated via research seminars, conference
presentations, journal articles, media releases and community
forums.
Trial registration number Australian New Zealand Clinical
Trials Registry ID 12616000630415; Pre-results.

Strengths and limitations of this study
►► To the best of our knowledge, this protocol is the first

that focuses on early detection and on the delivery
of preventative care and management of familial
hypercholesterolaemia (FH) in the primary care
setting. It is trialled within the Australian context but
builds on the consensus statements of the European
Atherosclerosis Society and the International FH
Foundation that FH care should ideally take place in
the primary care setting.
►► Our pragmatic approach using existing clinical
infrastructure enhances feasibility and sustainability
but pre-post intervention comparison is
acknowledged as potential limitation.
►► The general practitioner (GP) and practice nurse
(PN) team approach to phenotypic diagnosis and
the cascade testing of FH relatives is likely to prove
challenging initially from the GP/PN and patient
perspective—length of follow-up to determine
appropriate management of patients with FH will be
limited due to constraints of time and funding.
►► There is potential for impact on the outcomes and
interpretation as patients attending GP practices in
Australia are not registered to a single practice—
they may change residential address and be lost to
follow-up or register at more than one practice with
potential for duplication (or loss to follow-up if at
a non-participating practice); however, this will be
easily identified given the numbers of participants
followed up.
►► The potential for variability in compliance with
medications (eg, statins) and adherence to dietary
and lifestyle advice across practices and between
patients is acknowledged.

Introduction
Familial hypercholesterolaemia (FH) is
an autosomal dominant disorder of lipid
metabolism resulting in excessively high
plasma levels of cholesterol from birth. Left

Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539

1

Downloaded from http://bmjopen.bmj.com/ on October 24, 2017 - Published by group.bmj.com

Open Access
untreated, it can result in premature coronary artery
disease (CAD) due to accelerated onset of atherosclerosis.1 For men with FH, the risk of developing CAD
before age 50 years is 50% while for women it is 30% at
age 60 years.2 3 The accelerated development of atherosclerotic cardiovascular disease (CVD) by 20–40 years
as a consequence of inheriting FH means that children
and young adults have most to gain from early diagnosis
and treatment.4 It is estimated that between 1 in 500
and 1 in 200 persons have heterozygous FH yielding
a worldwide population estimate of 20 million cases.5
Of the estimated 45 000 with FH in Australia and New
Zealand,6 the vast majority remain undiagnosed and,
among those diagnosed, most remain undertreated.
However, lifelong treatment with diet and lifestyle
modifications together with lipid lowering therapy can
reduce the risk of CAD close to the non-FH population.7 Early diagnosis is therefore critical.
The 2011 Australian FH Model of Care (MoC)
primarily focused on specialist lipid clinics in tertiary
centres to augment the development of clinical services
for FH.8 The need to develop a corresponding MoC
suitable for the primary care setting is increasingly
recognised,8 especially in light of the vastly different
disease demographics of patients attending primary
and tertiary clinics (according to Bettering Evaluation
and Care of Health (BEACH)data, 8.4% of primary care
encounters are referred to medical specialists)9 and the
persisting low rates of FH detection and treatment in
the Australian population.8 10 Primary cares services are
the first point of contact with the health system and over
85% of the Australian population attend a general practitioner (GP) at least once annually.11 Thus, primary
care teams are ideally placed to play a more active
role in the detection and management of unsuspected
cases of FH in the community, thereby contributing to
addressing the gap that currently exists in the Australian health service.8
The key challenge for primary care is to develop a
systematic and sustainable approach to detect index
cases for FH in the community. Once this is achieved,
the next step is to progress to family cascade testing.
There is extensive evidence to show such an approach
would be clinically2 8 10 and financially12–14 effective.
The need to integrate the central role of primary care
with specialist lipid services to optimise the detection and management of FH in the community is
recognised.15 16 The provision of a community-based
MoC for FH involving a more comprehensive and
focused education programme for GPs, practice nurses
(PNs) and practice staff, improved communication with
cardiologists and pathology providers as well as support
from lipid specialists to help manage more difficult
high-risk patients with FH and to improve cascade
testing of relatives of index cases, has been suggested.16
In a regional Western Australian (WA) primary care
setting, three different approaches for FH detection were
successfully tested.17 These included (1) a community
2

pathology laboratory database (n=52 200); (2) a workplace-based occupational health assessment process
(n=1079), and (3) a general practice patient database
(n=41 100) to screen for increased CVD risk—a total
population of 94 379. A total of 1316 individuals subsequently had a detailed clinical assessment for FH and 86
participants were identified with clinical FH. Those with
Dutch Lipid Clinic Network Criteria (DLCNC)2 scores >5
were offered referral to lipid specialist clinic for further
review. Of the 59 individuals assessed by the lipid specialist
who underwent DNA testing, 11 (18.6%) were identified
to carry FH mutations.17
The study used the existing practice-based medical
and nursing services in the regional primary care
setting. The findings supported the potential development of an integrated screening programme capable
of combining the use of pathology services (including
interpretative comments on lipid profile) and the
involvement of the primary care team in detection
and management.17 The engagement of local GPs
and PNs in recalling and following up patients generated greater patient involvement in the screening
process. The preferred model used a two-stage process
where at-risk patients were identified through raised
low-density lipoprotein cholesterol (LDL-c) concentrations that were subsequently flagged by the GP-PN
team for review.
Bell et al18 examined whether individuals with FH
could be accurately identified in the primary care setting.
They concluded that GPs were able to accurately identify
individuals at high or low risk for FH using the DLCNC
score,2 thereby augmenting opportunistic FH detection
in the community. In addition, by increasing education
for the primary care team, the diagnostic accuracy of FH
detection in primary care could be enhanced.
With this in mind, Troeung et al19 designed an electronic data extraction tool (TARB-Ex) which enables
routine clinical information to be extracted from general
practice patient management software databases (Best
Practice Software) and identifies patients at potential
risk of FH for follow-up based on the DLCNC score. The
extraction tool has shown its capacity to identify patients
at increased risk of FH in the primary care setting,
comparing favourably with a manual assessment of FH
risk by the GP,19 thus facilitating an innovative and timesaving approach to improve both detection and subsequent management.
The current protocol is an innovative primary carebased diagnostic approach using phenotypic criteria as
per the DLCNC score rather than more expensive genetic
testing. Close relatives of index cases will be targeted for
cascade testing and appropriate treatment and lifestyle
modifications instituted. Most of this work will be undertaken in the less expensive community setting of general
practice. Lipid specialist assistance will be available for
more difficult and complex cases but it is anticipated
that most of the detection and management of FH will
occur in the primary care sector. The MoC is thus both
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539
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pragmatic and feasible with potential for considerable
immediate cost savings to the health sector.
Methods and analyses
Objective
To trial a primary care-based MoC for FH.
Hypothesis
Electronic data extraction from patient records facilitates
clinical review to improve the detection and management
of FH in general practice.
Study design
A pragmatic, cluster intervention study with pre-post
intervention comparisons.
Study setting
General practices in Australia. The study commenced in
five practices in WA in July 2016.
Eligibility criteria
Patients aged 18+ years, able to provide informed consent.
Primary outcomes
1. increase in number of index cases clinically identified;
2. reduction in LDL-c of treated cases.
Secondary outcomes
1. increase in the number of family cases detected/
contacted (including children);
2. cost implications of the method of care.
Study procedure
Community involvement
In June 2016, the investigation team worked with WA
Consumer and Community Health Research Network20
and included members of the FH Support Group21 and
FH Australasia Network22 to organise a ‘Community
conversation’ forum23 prior to study commencement in
WA. The aim of the forum was to reflect on aspects of
the study protocol including the preferred approach to
cascade testing of relatives.
Information sessions
Information sessions will be held at the start of each arm
of the study for all participating practices. These will be
convened as general sessions open to all participating
GPs and PNs and supplemented by the investigation team
undertaking location visits to each participating practice.
The sessions will include background information on
FH, the proposed method of care protocol, the process
of consenting patients to participate, data to be collected
during the research study and suggestions for cascade
testing processes. The content for these sessions will be
adapted from those previously undertaken.24 25
In addition, GPs and PNs will have the opportunity for
one-on-one consultation with the GPs on the research
team at each stage of the research protocol. This will
allow for specific discussion of individual patients.
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539

Figure 1 Steps involved in study protocol. CVD,
cardiovascular disease; FH, familial hypercholesterolaemia;
GP, general practitioner; PN, practice nurse.

Overall plan is outlined in figure 1 and timeline
is outlined in table 1.
Step 1: assessment of current practice
Qualitative (open-ended) and semiquantitative (scaled)
responses will be collected from GPs and PNs on current
practice (table 2). This aims to establish a baseline of GP,
PN and practice staff awareness and GP self-confidence in
diagnosing and managing FH.
Step 2: electronic screening
Using a validated electronic data extraction method
(TARB-Ex),19 electronic medical records of all patients
seen at the practice in the last 2 years with a recorded
blood LDL-c will be screened for potential FH risk.
TARB-Ex has an inbuilt standardising algorithm to nominally adjust cholesterol levels (see online supplementary information 1) of patients prescribed statins within
3
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Table 1 Study timeline
Activity
4 months
4 months

Employ additional staff, identify practices involved.
Study lead-in and set-up—staff commence, ethics applications, contact practices. Commence registry liaison.

4 months

Steps 1–4 and 8 of study protocol
Baseline data extraction and qualitative information collection
Commence training for GPs, PNs and practice staff.
List at-risk patients for recall.

12 months

Steps 5–8 of study protocol
Patients seen for management
Monitor management/compliance and registry data.
Relatives cascade tested/annotated attempts to contact family members.
Time estimation and cost data sourced
Qualitative information collected from practices
Study write-up
Information dissemination

6 months

GP, general practitioner; PN, practice nurse.

1 week to 6 months of the date of highest recorded cholesterol measurement. Potential FH risk is established using
a modified DLCNC score2 and a list of at-risk patients
generated. A list of all patients with an existing diagnosis
of FH will also be extracted to establish baseline numbers
of known FH cases at the practice.
Step 3: medical record review
As part of the intervention and in addition to the previously delivered information sessions, GP/PNs will receive

enhanced guidance and training on the assessment and
management of patients with FH via one-on-one and
face-to-face practice meetings and referred to online
information sessions.24 25 In consultation with the clinical investigative team (TB, AV and GFW), the GP/PN
team will then review the clinical records of potential
FH risk patients (those with TARB-Ex DLCNC scores ≥5)
identified in step 2 to determine if they are considered
at high risk of FH and require clinical assessment. Other

Table 2 Preintervention discussion schedule for general practice staff
1*
2

Discussion points

Reason

How would you rate your current knowledge of FH?
Prompt if needed 1 (no knowledge) to 5 (extremely knowledgeable)
How comfortable would you be with diagnosing FH?
Prompt if needed 1 (very uncertain) to 5 (extremely confident)

Establishing extent of
knowledge

3

How confident would you feel managing a patient with FH?
Prompt if needed 1 (very uncertain) to 5 (extremely confident)

4

Can you recall ever having a patient with FH previously?

5

Determining current
Before this study would you have considered a diagnosis of FH in patients with high
management of FH
cholesterol?
Yes:
►►How did you go about diagnosing the condition?
►►Have you used any guidelines for managing FH (if so whichones?)
►►How do you generally manage patient care in FH cases? (medication, lifestyle, and so on)
►►Have you referred any patients onto a lipid specialist (if so who did you refer to and how?)
►►Have you ever recommended patients contact family members for additional screening or
investigation for FH, or followed up family members yourself?
►►If yes how did you go about it?
►►How did your patients feel about their families being contacted?
No:
►►Was that because you were previously unaware of FH?
What would you usually do with a patient that presents with high cholesterol?
Determining current
management of patients
with hypercholesterolaemia

6

All prompt questions for general practitioner.
*Prompt question for practice nurse and practice manager.
FH, familial hypercholesterolaemia.

4
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potential causes of hypercholesterolaemia (cholestasis,
nephrotic syndrome, steroid use, hypothyroidism) also
need to be considered in the decision. Clinical records
of existing patients with FH identified in step 2 will also
be reviewed by the GP/PN team in consultation with the
clinical investigative team (TB, AV and GFW) to determine whether current treatment is optimal and/or if clinical reassessment is required.
Step 4: clinical assessment
The GP/PN will then recall the patients identified at
risk of FH and likely to benefit from clinical assessment
in order to update family and personal history, exclude
possible secondary causes and assess adherence to
cholesterol-lowering medications (if necessary). They
will also undertake clinical examination to check for
corneal arcus and tendon xanthomata. Information
on family history and the importance of undertaking
cascade testing of family members will also be flagged
by the GP/PN. The diagnosis of FH will be based on
the DLCNC score at clinical examination, and individuals with scores ≥6 will be regarded as having clinical
FH. Consultation with the clinical investigative team
(TB, AV and GFW) will be encouraged in confirming
FH diagnoses. All newly diagnosed index cases will be
consented into the study by the GP/PN. Patients with
existing FH identified in step 1 will also be recalled and
consented into the study. The general practice team
will be encouraged to work with the Australian FH
Registry26 27 to record information on newly diagnosed
patients as well as any existing patients with FH who are
currently unknown to the FH Registry.
Step 5: management and cascade testing
Management of patients is based on consensus opinion6 28
and is outlined in figure 2. Patients assessed as low-to-intermediate complexity FH will be managed by the GP/PN
with additional specialist support if required. High-complexity cases will receive additional support from the
specialist. Patients’ lipid levels and cholesterol-lowering
medication will be monitored (suggest every 3–6 months)
as will other lifestyle factors. The GP/PN team will be
responsible for cascade testing of FH relatives. Though
we have provided guidelines,28 this part of routine clinical
practice is likely to prove challenging for research practices initially both from the GP/PN and patients’ perspective. Additional support will be provided as required. In
addition, GPs will be encouraged to consent into the
study any new patients with FH they may identify as part
of usual care.
Step 6: study follow-up
At the end of 12 months, TARB-Ex will be rerun to identify the total number of new FH cases diagnosed over
the study period (including those identified through
TARB-Ex, cascade-tested cases and new cases to the
practice). Clinical records of all consented patients with
FH detected will be reviewed and data on treatment and
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539

Figure 2 Suggested management plan derived from: (1)
ref 28. (2) Brett, Watts, Garton-Smith, Bell, Vickery, Pang
and Arnold-Reed (2015): Familial hypercholesterolaemia:
challenges in primary care. Medicine Today 2015;
16(8): 20–26. CVD, cardiovascular disease; FH, familial
hypercholesterolaemia; GP, general practitioner; LDL-c, lowdensity lipoprotein cholesterol; PN, practice nurse.

most recent LDL-c levels will be extracted from medical
records to evaluate any change in LDL-c over the study
period. All patients diagnosed with FH will be encouraged to have their information included in the Australian FH Registry.
Step 7: follow-up qualitative interviews
Patient, GP, PN and practice staff perceptions of the
enablers and barriers and suggested improvements to
using the approach in addressing FH will be examined (tables 3 and 4). This will be achieved using
qualitative methodology which includes a triangulation of data collection methods including both semistructured interviews (face-to-face and telephone)
and focus groups (poststudy community feedback
sessions). The exact method will be guided by the
availability and preferences of the participants and
it is acknowledged that the different methodologies
used will elicit different information. For example,
the preference potentially from a time perspective
may be for GPs to complete a telephone interview.
Conversely, in order to achieve a balance of individual
perspectives, focus groups will be conducted among
patient groups across practices. Specialist views on
successes and failures on the overall process will also
be elicited (table 5).
Step 8: economic assessment
The economic implications of implementing the MoC
will be assessed. The costs of developing the TARB-Ex
screening protocol have been identified in a previous
paper.19 In addition, labour costs of implementing the
5
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Table 3 Discussion schedule for general practice staff postintervention
Discussion points

Reason

Section A: Knowledge improvement
1*
How would you rate your knowledge of familial
Establishing extent of knowledge
hypercholesterolaemia?
Prompt if needed 1 (no knowledge) to 5 (extremely knowledgeable)
2

How comfortable would you be with diagnosing FH?
Prompt if needed 1 (very uncertain) to 5 (extremely confident)

3

How confident would you feel managing a patient with FH?
Prompt if needed 1 (very uncertain) to 5 (extremely confident)

Section B: Effectiveness of proposed model of care for identification and management of FH
4

In terms of the training you received for identification and treatment Establishing usefulness of training sessions with
of FH, how did you feel about that process? Was it helpful or not? GP and staff
What did you like/dislike about it? What inclusion/exclusions, if any,
would you like to see?

5

How do you feel about the follow-up care for FH? Do you feel it
was beneficial to your patients? Why/why not? And did you find it
beneficial? Why/why not?

Establishing effectiveness of introduced model of
care

6

Did you need to contact the hospital lipid specialist? If yes, how
well did the communication with them work? If not so well, was
there anything you would like to see improve? If well, what were
the elements that were particularly good?

Seeking out from participant any unique challenges
within a practice setting that may create barriers
and difficulties

Section C: Establishing effectiveness of screening process in identifying patients with FH
7*

Did you feel the TARB-Ex tool was a useful add-on to your existing Establishing the practicality of the screening tool—
software? Was it easy for you and your staff to use? Can you give was it efficient?
any examples of what worked well/not so well?

8

Did you feel that the screening process overall (TARB-Ex extraction Establishing perceived effectiveness of the
and GP review of patient files) was helpful in detecting patients
screening process—did it work?
with FH? Was it an efficient process? Why/why not?

9

What aspect of the overall screening process did you find the
hardest? What area could improve?

Identifying potential improvement and increased
efficiency

Section D: Establishing the effectiveness of family cascade testing for FH
*Preamble: part of the intervention required family members to be
contacted and, if possible, tested for FH. I’d like to ask you a few
questions around that process.
10*

How did you go about contacting families and the cascade
testing? What did you find easy or difficult about this process?

Establishing the effectiveness of the intervention
within the practice—was it practical?

11*

Do you think that cascade testing benefited the families of those
diagnosed with FH? If yes/no, why do you feel this way? Overall,
did you see any increase in awareness within patients and their
families regarding FH?

Establishing the perceived patient benefits of
cascade testing and a family-based model of
care—did it work?

12*

Did you encounter any examples of resistance to family screening?

Section E: Overall intervention feedback
13
14

Do you think you are likely to continue with this method of care in
your practice? Why/why not?
Would you have any comments or suggestions that we have not
mentioned about ways the process could work going forward?

Determining sustainability

All prompt questions for the GP.
*Practice manager and practice nurse.
FH, familial hypercholesterolaemia; GP, general practitioner.

MoC including costs of training GPs and PNs in screening
patients will be tracked at each practice. Furthermore,
administrative data from each primary care practice will
be sourced to identify the costs of managing patients with
6

FH after they have been identified. Where FH cases are
referred to specialist care, administrative data from the
tertiary centres they were referred to will be sourced to
identify the specialist costs associated with managing these
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539
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Table 4 Discussion schedule for patients postintervention

1

Discussion points

Reason

Preamble: I’d just like to thank you for your time. We have recently been part
of introducing a new model of care for familial hypercholesterolaemia into the
practice. I want to ask you a bit about FH and the approach to care you have
been given.
Approximately how long have you been attending [practice name]? Do you
tend to see the same Dr or different GPs?

Trying to establish patient familiarity and
comfort level with the practice

2

You were contacted recently to attend [Dr or practice name], and based on
your medical records you were investigated for FH [confirm] and then given a
diagnosis of FH [confirm].

Confirming diagnosis of FH

3

Were you clear as to why you were being contacted? How did you feel about
that process?

Assessing clarity of communication

4

Were you able to ask questions? If you did ask questions, were your questions Evaluating impact of initial screening and
answered and were the answers satisfactory (enabling you to understand the contacting process on the patient
condition?)

5

Can you describe what the health implications might be for someone who has
been diagnosed with FH?

Evaluating if FH education has been
integrated successfully from the GP to
the patient

6

Your GP also suggested your family members be contacted to see if they
could have FH. How do you feel about this? Did you consent to having family
members contacted? Are your family members also patients of this practice?

Assessing the cascade testing
procedures from patients’ point of view

7

How did this process come about, did you contact them yourself or did the
practice?

Assessing the most practical and
efficient/preferred method of family
contacting

8

Do you have anything else you would like to add in regard to this conversation
about FH?

FH, familial hypercholesterolaemia; GP, general practitioner.

patients. These costs can then be averaged to provide a
mean cost per FH case.
Sample size calculation
Our sample size calculation is based on the number of
patients needed to detect a statistically significant reduction in LDL-c at 12-month follow-up. Based on clinical
audit data from three WA practices, the expected reduction in LDL-c for patients with FH receiving intensive statin
treatment over 12 months is 2.83±1.15 mmol/L (n=13;
Vickery, personal communication) versus 0.35 mmol/L
in the control arm based on data from our previous study
based on usual care.29 This is an expected mean difference
of 2.48 mmol/L. If we assume a more conservative mean
difference of 2.0 mmol/L, we will need 41 patients with

clinically diagnosed FH to adequately power our study at a
0.80 level with a type I error probability of 0.05 (two tailed).
Data from our pilot study19 suggest the prevalence of
FH in general practice is 1:412. Therefore, to detect 41
cases of clinically diagnosed FH, we will need to screen
16 892 patients.
To adjust for variation across five practices (clustering
effect), we have applied a design effect inflation adjustment of 1.6 based on an assumed intraclass correlation
coefficient for process variation in primary care of 0.15.30
This estimates to a required total sample size of at least
27 027.
Pilot data19 show that we are likely to have on average
5–8000 patients per practice who have been seen in the

Table 5 Discussion schedule for specialist staff postintervention
1

2

Discussion points

Reason

Were you contacted by any of the GP teams? If yes, how well did the
communication with them work? If not so well, was there anything you would
like to see improve? If well, what were the elements that were particularly
good?
How do you feel about the follow-up process worked? Do you feel it was
beneficial? Why/why not?

Seeking out from participant any unique
challenges within a practice setting that
may create barriers and difficulties
Establishing effectiveness of introduced
model of care

GP, general practitioner.
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539
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last 2 years. Hence, the study is adequately powered to
achieve the primary outcome.

a clinical study, data will be retained for 15 years after
publication.

Expected extent of cascade testing to inform proposed sample size
Recruitment from five practices will generate an expected
66 index cases. It is expected that up to 50% of relatives will
be diagnosed with FH,31 potentially providing between 66
and 125 FH cases. However, it is acknowledged that not
all relatives will be followed up as they may not be patients
of participating practices or may decline follow-up.

Data analysis
Statistical methods
Analyses will be conducted using Stata V.13. Descriptive
statistics will be used to outline the number of patients
at each point of the study (screened, at risk, followed
up and clinically diagnosed with FH). At 12 months, the
number of new index cases and number of new family
cases detected will be reported. FH prevalence will be
calculated as the total number of index cases as a proportion of all active patients. The FH detection rate will be
calculated as the number of new, clinically identified
index cases at 12 months as a proportion of the number
of at-risk patients identified through TARB-Ex at baseline. Change in LDL-c will be examined using multilevel
mixed-effects modelling. LDL-c level at 12 months will
be the dependent variable. Random effects included: GP
(cluster effects) and time (repeated observations on the
same individual). Analysis will also be adjusted for sex and
age.

Outcome measures
Quantitative data
►► number of known index cases of FH and new cases
identified through TARB-Ex;
►► highest LDL-c measure ever;
►► LDL-c measure closest to baseline;
►► LDL-c measure closest to 12-month follow-up;
►► statin type, dose and length of time prescribed over
study period;
►► other CVD risk factors present;
►► attempts recorded in notes to contact family members;
►► number of family members with existing or new FH
diagnosis or contacted.
Cost data
implementation and extraction of patient data using
TARB-Ex;
►► GP/PN time involved in manual screening of patient
records;
►► personnel time/resources involved in recall of
patients;
►► GP/PN time (from billing schedules) involved in clinical screening of patient records;
►► patient management costs based on number of visits,
length of visits for GP practice and specialist tertiary
referrals over the course of the study;
►► number and type of prescriptions issued.
►►

Qualitative data
Patient and clinical staff views will be assessed using items
listed in tables 2–5.
Data management
Data will be deidentified prior to records leaving the
GP practice. Only deidentified data will be used by
researchers. Audio recordings collected as part of the
interviews and focus groups will be kept in secure, locked
cabinets. No identifying patient information (eg, names,
age) will be recorded during the interviews. Research
data will be stored in a password-protected database on
a secure server. This network to which the server belongs
is protected by multiple firewalls to restrict outside, unauthorised access. Only aggregated, non-identifiable data
will be produced in hard copy and this will be maintained
in a ‘restricted-access’ locked cabinet located in a lockable office when not in direct use. Only specified research
personnel will be permitted access to the data. As this is
8

Cost efficiency analysis
Costs collated from the start of the study to the endpoint
at 12 months will be compared against historical costs
sourced from tertiary centres for treating and managing
FH cases. This will provide an indication of expenditures
or savings from adopting the primary care-based MoC.
Qualitative analysis
Qualitative analysis of interview data will be thematically analysed using QSR NVivo V.10. Thematic analysis
allows for identification, analysis and detailed reporting
of repeated themes within data.32 Interviews will be
audio-recorded and transcribed verbatim, then coded
for key themes (words, sentences or phrases). An experienced qualitative researcher will be guiding the analysis.
Two researchers will be analysing the data to increase reliability of coding and to enable a consensus regarding key
themes and subthemes that emerge.
Ethics and dissemination
Ethics approval
The University of Notre Dame Australia Human Research
Ethics Committee Protocol ID: 0 16 067F. Australian New
Zealand Clinical Trials Registry ID: 12616000630415.
Patient consent
The protocol involves the retrospective screening of
patient records, clinical management of patients with FH
and eliciting patient and clinic staff views on the method
of care. It would not be practical to obtain consent from
all patients whose results are to be electronically screened
(steps 2 and 6). For patients screened, only deidentified
aggregate data will be used for research analysis. For
patients who are confirmed as having FH, management
will be under GP care but patient-specific information
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539
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(steps 4 and 5) will be required for analysis. Consent to
use this information will be obtained by the GP/PN. At
consultation (step 4), the GP will inform the patient of
the study. If the patient is confirmed as having FH, the
GP will provide the patient with an information sheet
and consent form. If the patients consent to be part of
the study they will be considered index patients. If they
do not consent they will not be followed up for research
purposes, but this will not affect treatment received from
their GP using study protocol. Step 4 will also provide the
opportunity to initiate discussions with those who have
consented to be part of the study for potential cascade
testing of other family members should the individual
patient be considered at high risk for FH. If the family
member(s) identified are part of the same practice or
seen by the same GP, they can also be considered as an
index case and consented to be part of the study. If the
new family member(s) identified are not part of the
same practice/GP then they will be contacted by their
GP (protocol outlined in Brett et al28) but will not be
consented to the study.
GP, PN, practice managers and specialist consent
Steps 1 and 7 involve patient, GP, PN, practice staff and
specialist staff perceptions of the success and/or barriers
and suggested improvements to the approach. Informed
consent will be obtained. The researcher will explain to
the participants the purpose of the study and provide
them with an information sheet. Consent will be written
or verbally recorded.
Confidentiality
Patient medical records will not be removed from the
clinic for research purposes. No identifying patient information (eg, names, age) will be recorded during the
interviews.
Dissemination
Information will be disseminated via research seminars,
conference presentations, journal articles and media
releases. Community dissemination is envisaged through
community advocacy groups involved in the community
engagement at study set-up.
Access to data
The funders shall always be allowed to request full access
to all deidentified data collected in the study in a deidentified form as long as this does not violate Australian legal
requirements, including, but not limited to, the Privacy
Act 1988,33 for research, educational and registration
purposes after the conclusion of the study. The funders
may request an independent third party to undertake a
second evaluation and analysis of data collected in the
study.
Ethical considerations
From a patient management perspective, obtaining
permission for cascade testing relatives will need to be
considered and the protocol outlines suggestions of how
Arnold-Reed DE, et al. BMJ Open 2017;7:e017539. doi:10.1136/bmjopen-2017-017539

this could be done.28 Relatives who are not patients of
the practice should be advised by the index case of their
potential high FH risk and encouraged to have their
LDL-c levels assessed at their local practice. If there is
any uncertainty, Commonwealth and State Legislation,
National Health and Medical Research Council guidelines and local health service protocols about disclosure of
medical information without consent should be followed.
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